查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862930

静脉注射免疫球蛋白市场依最终用户、产品类型、患者类型、通路和适应症划分－2025-2032年全球预测

Intravenous Immunoglobulin Market by End User, Product Type, Patient Type, Distribution Channel, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，静脉注射免疫球蛋白市场规模将达到 23.1 亿美元，复合年增长率为 7.12%。

主要市场统计数据
基准年 2024 13.3亿美元
预计年份：2025年 14.3亿美元
预测年份：2032年 23.1亿美元
复合年增长率 (%) 7.12%

本书清晰权威地阐述了静脉注射免疫球蛋白如何成为现代免疫疗法在各种临床环境和不断变化的监管要求中的基础。

静脉注射免疫球蛋白在现代免疫疗法中发挥核心作用，是多种临床适应症的重要治疗方法。临床医生依靠这些血浆衍生产品来调节自体免疫疾病、血液系统疾病、免疫力缺乏以及某些神经系统疾病的免疫反应。在现代医学中，静脉注射免疫球蛋白因其作用机制广泛且适用于住院、门诊病人和专科护理等多种医疗环境而备受青睐，其产品组合涵盖了临床急症和长期疾病管理。

生产製造创新、完善的临床指南以及监管机构对可追溯性的重视，正在重塑静脉注射免疫球蛋白的供应链和治疗用途。

静脉注射免疫球蛋白领域正经历着变革性的转变，这主要得益于生产技术的进步、临床实践的转变以及监管机构对产品来源的日益重视。新的生产方法以及改进的纯化和製剂技术降低了不利事件的发生率，延长了保质期，并实现了液体剂型的稳定性，从而影响了医院的用药决策和门诊给药模式。同时，临床医生也在根据不断累积的真实世界数据优化适应症和给药策略，使临床指南与实际应用更加契合。

关税变化对全球血浆采购、生产经济性和免疫球蛋白疗法采购韧性的连锁反应

关税及相关贸易措施的实施可能会对严重依赖跨境血浆采购和国际生产网络的全球治疗领域产生连锁反应。影响原材料、包装材料或成品的关税调整可能会对采购团队和医院药房造成额外的成本压力，迫使製造商重新评估其筹资策略以及与供应商和经销商的合约结构。作为应对措施，企业可能会寻求促进本地生产或实现供应链多元化，以减少对单一贸易体系的依赖。

将市场进入趋势与医疗环境、产品配方、患者人口统计特征、分销管道和临床适应症联繫起来的综合細項分析

对细分市场的详细分析揭示了临床需求、製剂偏好和分销管道趋势相互交织，共同塑造使用模式的领域。最终使用者考虑涵盖居家医疗、医院和专科诊所等场所，其中医院进一步细分为私立和公立机构，专科诊所则细分为血液科、免疫科和神经科。这些区分至关重要，因为管理环境会影响管理物流、监控要求和合约方式。私立医院和专科诊所通常与公立医院协商不同的报销和采购条款，而居家医疗需要与护理服务部门协调并进行低温运输配送。

影响美洲、欧洲、中东和非洲以及亚太地区供应链韧性、监管力度和临床应用模式的区域趋势

区域趋势塑造了从捐赠血浆到患者的治疗路径，每个宏观区域都有其独特的监管、物流和需求侧因素。在美洲，完善的血浆采集基础设施、临床医生对静脉注射免疫球蛋白适应症的深刻理解以及先进的医院环境促进了其广泛应用，而区域支付方的政策和采购框架则影响着产品的选择和合约签订方式。公立和私立医疗保健系统之间的差异、专科诊所的作用以及门诊输液服务的密度，都会影响全部区域的治疗方法实施和报销方式。

对血浆来源、生产规模和临床证据的策略性投资如何使领先的生产商和分销合作伙伴脱颖而出

产业主要参与者正努力应对复杂的市场环境，在这个环境中，规模、供应安全和合规性至关重要。主要企业正投资于上游血浆来源、扩大血浆分离生产能力，并加强病原体减少和分析检测，以提高产品的安全性和一致性。血浆采集网路与生产者之间的策略联盟日益普遍，旨在确保原料来源并降低供应中断的风险。同时，各公司正透过改进製剂技术、拓展适应症产品系列以及附加价值服务（例如患者援助计划和输液中心合作）来实现差异化竞争。

为製造商和供应商提供切实可行的策略，以确保供应链安全、增强临床应用机会并优化商业管道。

产业领导者应采取多维度策略，平衡供应韧性、临床参与和商业性灵活性。加强与血浆采集网路的上游伙伴关係，并投资区域血浆分离能力，将有助于缩短前置作业时间，同时降低贸易中断和关税风险。同时，透过投资改进配方和分析方法来增强产品差异化，将有助于提升产品在医保目录的排名，并推动其在住院和门诊环境中的应用。

为了检验关键发现，我们采用了严格的混合方法研究框架，结合了专家访谈、监管分析和供应链情境分析方法。

我们的研究途径结合了多方面的证据基础和系统性检验，以确保研究结果的可靠性和可操作性。主要研究包括对血液科、免疫科和神经科的专科临床医生、公立和私立医院的采购人员、药房主任以及血浆采集和分离机构的高级管理人员进行深度访谈。这些访谈提供了关于临床实践、合约动态和营运限制的详细观点，并用于检验从二手资讯中观察到的趋势。

整合不断变化的临床、运作和政策因素，这些因素决定了免疫球蛋白疗法的可及性、安全性和治疗价值。

儘管静脉注射免疫球蛋白仍然是治疗多种免疫学、血液学和神经病学疾病的关键治疗方法，但其研发、采购和供应模式正在迅速变化。生产技术的进步和更严格的监管要求提高了产品品质和安全性，而供应链策略和区域供给能力的转变正在重塑其获取途径。临床医生、支付者和医疗系统将越来越重视循证用药、透明且稳健的采购管道，以确保治疗的连续性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 生物类似免疫球蛋白上市对标准静脉注射免疫球蛋白疗法定价和应用的影响
  • 透过整合个体化给药演算法优化静脉注射免疫球蛋白疗法的效率和疗效
  • 扩大静脉注射免疫球蛋白在自体免疫神经系统疾病和罕见疾病治疗的应用
  • 供应链多元化策略旨在缓解血浆短缺并确保静脉注射免疫球蛋白（IVIG）的稳定供应。
  • 监管协调工作旨在加速下一代静脉注射免疫球蛋白产品的全球核准
  • 分馏过程的技术进步提高了静脉注射免疫球蛋白产品的纯度和安全性。
  • 静脉注射免疫球蛋白（IVIG）在皮肤疾病中的仿单标示外使用日益增多，促使人们进行新的临床安全性研究。
  • 过渡到居家静脉注射免疫球蛋白（IVIG）模式可提高患者的便利性和医疗保健成本效益。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依最终使用者分類的静脉注射免疫球蛋白市场

  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
    • 血液科诊所
    • 免疫诊所
    • 神经内科诊所

9. 依产品类型分類的静脉注射免疫球蛋白市场

  • 高纯度免疫球蛋白
  • 通常是免疫球蛋白
    • 液体
    • 冻干产品

10. 依患者类型分類的静脉注射免疫球蛋白市场

  • 成人
  • 老年人
  • 儿童

11. 依分销管道分類的静脉注射免疫球蛋白市场

  • 直销
  • 医院药房
  • 零售药房
  • 批发商

12. 依适应症分類的静脉注射免疫球蛋白市场

  • 自体免疫疾病
    • Guillain-Barré二氏症候群
    • 免疫性血小板缺乏紫斑症
    • 川崎病
  • 血液疾病
    • 新生儿溶血病
  • 免疫力缺乏
    • 原发性免疫力缺乏缺陷症
    • 次发性免疫力缺乏
  • 神经系统疾病
    • 慢性脱髓鞘多发性神经炎
    • 多灶性运动神经病变

13. 各地区静脉注射免疫球蛋白市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 依组别分類的静脉注射免疫球蛋白市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国静脉注射免疫球蛋白市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Baxter International Inc.
    • BIoTest AG
    • Bio Products Laboratory Limited
    • Kedrion SpA
    • LFB SA
    • Shanghai RAAS Blood Products Co., Ltd.
Product Code: MRR-FF012EDC38B0

The Intravenous Immunoglobulin Market is projected to grow by USD 2.31 billion at a CAGR of 7.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.33 billion
Estimated Year [2025] USD 1.43 billion
Forecast Year [2032] USD 2.31 billion
CAGR (%) 7.12%

A clear, authoritative framing of how intravenous immunoglobulin underpins modern immunotherapy across diverse clinical settings and evolving regulatory expectations

Intravenous immunoglobulin occupies a central role in modern immunotherapy, serving as a critical therapeutic modality across a diverse set of clinical indications. Clinicians rely on these plasma-derived preparations to modulate immune responses in autoimmune, hematological, immunodeficiency, and selected neurological disorders. In contemporary practice, intravenous immunoglobulin is valued both for its broad mechanism of action and for its adaptability across inpatient, outpatient, and specialty care settings, making it a product class that intersects clinical urgency and long-term disease management.

Recent advances in manufacturing and quality control have elevated product consistency and safety profiles, while regulatory scrutiny and supply chain dynamics continue to shape access and utilization. The therapeutic landscape is being influenced by evolving clinical guidelines, greater emphasis on evidence-based use, and the integration of novel indications supported by emerging clinical data. As a result, stakeholders from clinicians to procurement leaders need nuanced insights into how clinical practice, manufacturing scale, and distribution channels interact to determine availability, therapeutic sequencing, and patient outcomes.

How manufacturing innovation, clinical guideline refinement, and regulatory emphasis on traceability are reshaping supply chains and therapeutic use of intravenous immunoglobulin

The intravenous immunoglobulin landscape is undergoing transformative shifts driven by advances in manufacturing, changing clinical practice, and heightened regulatory emphasis on product provenance. New manufacturing approaches and improvements in purification and formulation have reduced adverse event profiles and enabled longer shelf life and more stable liquid presentations, which in turn influence hospital formulary decisions and outpatient administration models. Concurrently, clinicians are refining indications and dosing strategies based on accumulating real-world evidence, prompting tighter alignment between clinical guidelines and utilization.

Supply chain resilience has become a strategic priority as plasma sourcing, donor recruitment, and international logistics face increasing scrutiny. This has spurred vertical integration, strategic partnerships between plasma suppliers and manufacturers, and investment in regional processing capacity. Regulatory agencies are emphasizing traceability and pathogen safety, and health systems are responding with more rigorous procurement standards and contingency planning. Collectively, these shifts are altering where and how intravenous immunoglobulin is produced, distributed, and administered, pressing industry participants to innovate across clinical, operational, and commercial domains.

The cascading effects of tariff changes on global plasma sourcing, production economics, and procurement resilience for immunoglobulin therapies

The imposition of tariffs and related trade measures can have a cascading influence on a global therapeutic class that depends heavily on cross-border plasma procurement and international manufacturing networks. Tariff adjustments affecting inputs, packaging materials, or finished products introduce additional cost pressure that procurement teams and hospital pharmacies must manage, and they can prompt manufacturers to re-evaluate sourcing strategies and contractual structures with suppliers and distributors. In response, firms may pursue localized production or diversify supplier bases to reduce exposure to a single trade regime.

Beyond immediate cost implications, tariffs influence contract negotiations and long-term strategic choices. They may accelerate moves toward regionalization of supply chains, encourage investments in domestic plasma collection and fractionation, or alter the economics of exporting finished product. Payers and hospital systems may shift purchasing patterns to prioritize products with more predictable landed costs, and manufacturers might adapt pricing structures or absorb a portion of tariff-related expenses to maintain competitive positioning. Ultimately, tariffs reshape the calculus around procurement resilience, supplier relationships, and regional manufacturing footprints in ways that require proactive commercial and operational adjustments.

Comprehensive segmentation analysis linking care settings, product formulations, patient demographics, distribution channels, and clinical indications to access dynamics

A granular view of segmentation reveals where clinical demand, formulation preferences, and channel dynamics intersect to shape utilization patterns. End-user considerations span home care, hospital, and specialty clinic settings, with hospitals further differentiated into private and public institutions and specialty clinics segmenting into hematology, immunology, and neurology practices. These distinctions matter because administration setting influences dosing logistics, monitoring requirements, and contracting approaches; private hospitals and specialty clinics often negotiate different reimbursement and procurement terms than public hospitals, and home care requires coordination with nursing services and cold-chain delivery.

Product-type segmentation distinguishes high purity immunoglobulin from standard preparations, and among standard products the formulation choice between liquid and lyophilized options affects storage, reconstitution workflow, and suitability for different care settings. Patient type segmentation identifies adult, geriatric, and pediatric populations, each with unique dosing paradigms and safety considerations that influence clinical protocols and payer coverage decisions. Distribution channel segmentation captures direct sales, hospital pharmacy supply, retail pharmacy dispensing, and wholesale distribution pathways, reflecting how procurement, inventory management, and service-level agreements vary across stakeholders. Indication-based segmentation encompasses autoimmune diseases, hematological conditions, immunodeficiency disorders, and neurological disorders, with autoimmune subcategories such as Guillain-Barre syndrome, immune thrombocytopenic purpura, and Kawasaki disease; hematological focus on hemolytic disease of the newborn; immunodeficiency subtypes including primary and secondary forms; and neurological emphasis on chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Integrating these segmentation lenses clarifies where clinical demand concentrates, how supply models must adapt, and which channels are most critical for timely patient access.

Regional dynamics driving supply chain resilience, regulatory rigor, and clinical adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape how therapies move from donor plasma to patients, and each macro-region presents distinct regulatory, logistical, and demand-side factors. In the Americas, established plasma collection infrastructure, strong clinician familiarity with intravenous immunoglobulin indications, and advanced hospital settings support broad utilization, while regional payer policies and procurement frameworks influence product selection and contracting approaches. Differences between public and private systems, the role of specialized clinics, and the density of outpatient infusion services all affect how therapies are administered and reimbursed across the region.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with national pricing and reimbursement variability. Several countries in this region emphasize stringent traceability and pathogen safety requirements, and both public procurement mechanisms and private specialty networks play roles in access. Investment in regional fractionation capacity and growing attention to supply security are shaping strategic priorities. In Asia-Pacific, rapid healthcare infrastructure expansion, rising clinical adoption across tertiary centers, and increasing investment in plasma collection capacity are notable. However, challenges persist related to distribution logistics, cold-chain reliability, and alignment between clinical guideline adoption and payer coverage. Taken together, regional differences influence manufacturer strategy, clinical adoption timelines, and the design of distribution partnerships to ensure consistent patient access.

How strategic investments in plasma sourcing, manufacturing scale, and clinical evidence are differentiating leading producers and distribution partners

Key industry participants are navigating a complex environment that rewards scale, supply security, and regulatory compliance. Leading firms are investing in upstream plasma sourcing, expanding fractionation capacity, and enhancing pathogen reduction and analytical testing to strengthen product safety and consistency. Strategic alliances between plasma collection networks and manufacturers are increasingly common, aiming to secure raw material streams and reduce exposure to supply disruptions. At the same time, companies are differentiating through formulation advances, portfolio breadth across indications, and value-added services such as patient support programs and infusion center partnerships.

Competitive dynamics also reflect varied go-to-market models: some organizations emphasize direct sales to large hospital systems and integrated health networks, while others prioritize distribution via hospital pharmacies, retail channels, or wholesale partners to reach a broader clinical base. Mergers, targeted acquisitions, and technology partnerships that improve manufacturing yield or reduce cycle time are shaping the competitive map. Additionally, a focus on evidence generation, real-world outcomes studies, and targeted clinical programs is enhancing payer conversations and supporting label expansions or guideline inclusion for new and established indications.

Practical strategic moves for manufacturers and suppliers to secure supply chains, strengthen clinical access, and optimize commercial channel alignment

Industry leaders should adopt a multidimensional strategy that balances supply resilience, clinical engagement, and commercial agility. Strengthening upstream partnerships with plasma collection networks and investing in regional fractionation capabilities will reduce exposure to trade disruptions and tariffs while improving lead times. Simultaneously, enhancing product differentiation through formulation improvements and investment in analytical methods will support formulary positioning and facilitate adoption across inpatient and outpatient settings.

Commercially, organizations should tailor channel strategies to account for differences in direct hospital procurement, hospital pharmacy distribution, retail dispensing, and wholesale networks, and align contracting and value propositions with the specific needs of private versus public institutions and specialty clinics. Clinically, partnering with key opinion leaders across hematology, immunology, and neurology to build robust real-world evidence can accelerate guideline adoption and clarify appropriate utilization across adult, geriatric, and pediatric populations. Finally, firms should implement dynamic pricing and risk-sharing mechanisms that address payer concerns while preserving access, and maintain transparent communication with regulators and health systems to anticipate policy shifts and ensure uninterrupted patient care.

A rigorous mixed-methods research framework blending expert interviews, regulatory analysis, and supply-chain scenario techniques to validate key insights

The research approach combined a multi-source evidence base with structured validation to ensure robust findings and actionable insights. Primary research included in-depth interviews with clinicians across hematology, immunology, and neurology specialties, procurement leaders from private and public hospitals, pharmacy directors, and senior executives in plasma collection and fractionation organizations. These conversations provided granular perspectives on clinical practice, contracting dynamics, and operational constraints, and were used to validate trends observed in secondary sources.

Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, manufacturing quality standards, and publicly available filings and technical materials. Analytical methods integrated qualitative synthesis of stakeholder interviews with process mapping of supply chains, scenario analysis of trade and tariff impacts, and comparative review of formulation and distribution models. Quality assurance steps included cross-validation of interview findings against regulatory and clinical literature, internal expert review, and methodological transparency about data limitations and potential biases. This layered approach ensured the report's conclusions rested on convergent evidence and practitioner-informed interpretation.

Synthesis of the evolving clinical, operational, and policy drivers that will determine access, safety, and therapeutic value for immunoglobulin therapies

Intravenous immunoglobulin remains a cornerstone therapy across a range of immunologic, hematologic, and neurologic indications, but the environment in which it is developed, sourced, and delivered is evolving rapidly. Manufacturing advances and tighter regulatory expectations have improved product quality and safety, while shifts in supply chain strategy and regional capacity are reshaping access dynamics. Clinicians, payers, and health systems will increasingly demand evidence-aligned use, transparent provenance, and resilient procurement pathways to ensure continuity of care.

Looking ahead, stakeholders who proactively invest in secure plasma sourcing, flexible manufacturing footprints, and rigorous clinical evidence generation will be best positioned to navigate tariff pressures, distribution complexities, and shifting care models. Cross-sector collaboration among manufacturers, plasma collection networks, clinicians, and payers will be essential to sustain availability and to optimize therapeutic value for patients across diverse care settings and regions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of biosimilar immunoglobulin launches on pricing and adoption of standard IVIG therapies
  • 5.2. Integration of personalized dosing algorithms to optimize IVIG treatment efficiency and outcomes
  • 5.3. Growing use of intravenous immunoglobulin in autoimmune neurology and rare disease therapies landscape
  • 5.4. Supply chain diversification strategies to mitigate raw plasma shortages and ensure IVIG availability
  • 5.5. Regulatory harmonization initiatives accelerating approval of next generation IVIG formulations globally
  • 5.6. Technological advancements in fractionation processes driving higher purity and safety of IVIG products
  • 5.7. Increasing off-label use of IVIG in dermatological conditions driving new clinical safety studies
  • 5.8. Shifts towards home-based IVIG administration models enhancing patient convenience and healthcare cost efficiencies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intravenous Immunoglobulin Market, by End User

  • 8.1. Home Care
  • 8.2. Hospital
    • 8.2.1. Private Hospital
    • 8.2.2. Public Hospital
  • 8.3. Specialty Clinic
    • 8.3.1. Hematology Clinic
    • 8.3.2. Immunology Clinic
    • 8.3.3. Neurology Clinic

9. Intravenous Immunoglobulin Market, by Product Type

  • 9.1. High Purity Immunoglobulin
  • 9.2. Normal Immunoglobulin
    • 9.2.1. Liquid
    • 9.2.2. Lyophilized

10. Intravenous Immunoglobulin Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Intravenous Immunoglobulin Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Wholesale Distributor

12. Intravenous Immunoglobulin Market, by Indication

  • 12.1. Autoimmune Diseases
    • 12.1.1. Guillain-Barre Syndrome
    • 12.1.2. Immune Thrombocytopenic Purpura
    • 12.1.3. Kawasaki Disease
  • 12.2. Hematological Conditions
    • 12.2.1. Hemolytic Disease Of The Newborn
  • 12.3. Immunodeficiency Disorders
    • 12.3.1. Primary Immunodeficiency
    • 12.3.2. Secondary Immunodeficiency
  • 12.4. Neurological Disorders
    • 12.4.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 12.4.2. Multifocal Motor Neuropathy

13. Intravenous Immunoglobulin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intravenous Immunoglobulin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intravenous Immunoglobulin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Limited
    • 16.3.2. Grifols, S.A.
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Octapharma AG
    • 16.3.5. Baxter International Inc.
    • 16.3.6. Biotest AG
    • 16.3.7. Bio Products Laboratory Limited
    • 16.3.8. Kedrion S.p.A.
    • 16.3.9. LFB S.A.
    • 16.3.10. Shanghai RAAS Blood Products Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INTRAVENOUS IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INTRAVENOUS IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRAVENOUS IMMUNOGLOBULIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNOLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HIGH PURITY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY WHOLESALE DISTRIBUTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNE THROMBOCYTOPENIC PURPURA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY KAWASAKI DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMOLYTIC DISEASE OF THE NEWBORN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HOSPITAL, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY SPECIALTY CLINIC, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY NORMAL IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY HEMATOLOGICAL CONDITIONS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA INTRAVENOUS IMMUNOGLOBULIN MARKET SIZE, BY IMMUNODEFICIENCY DISORD